loader image

Egis

We are one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.

In the 2020/2021 financial year, Egis Group generated net sales of EUR 542 millionBesides Hungary, we sell our products under Egis’ brand names in 17 countries through our network of subsidiaries and representative offices.

Our products range from active ingredients, through tablets and injections, to galenic (i.e. liquid and semi-solid) formulations and are available in 61 countries in total through our network of subsidiaries and representative offices or partners. Last financial year our portfolio consisted of 634 products that belonged to 167 product lines and contained 151 active ingredients.

Our focus lies on treating diseases of the cardiovascular and central nervous systems; however, we also provide modern treatment solutions in the fields of oncology and women’s health. In 2013, we launched our first biosimilar monoclonal antibody product. This was also the first biosimilar monoclonal antibody (mAb) in the European Union. Since then we launched three additional biosimilar drugs.

As one of the companies in the Central Eastern European region firmly committed to innovation, we devote about 45 EUR million yearly to R&D. Our research and development activities focus on high-quality, value-added branded generic products.

In the last twenty years, we have invested around EUR 770 million in improvements — such as modernizing the complete process of our finished product manufacturing, as well as establishing state-of-the-art R&D centers in Hungary. Development of highly potent (meaning having significant biological activity in very small doses) drug substances and finished products has also become possible at our site in Budapest, where the comprehensive modernization of the traditional technology of active ingredient manufacturing has also been completed. Some large-scale development activities have been carried out at our site in Körmend: a new galenic plant was inaugurated in September 2019, while  two technology-intensive developments were launched in autumn 2021: the first phase of the major extension of one of our existing packaging plants was completed and capacity to manufacture  special medicines (typically oncology products) was established.  

Alotendin


Alzepil


Aripegis


Betadine


Cardilopin


Clostilbegyt


Crurovit


Dopegyt


Egolanza


Halixol


Hartil Amlo


Hartil


Ketilept


Letiram


Lidocain


Lodigrel


Lucetam


Milurit


Nitromint


Parlazin


Peritol


Pipolphen


Pollezin


Rosulip


Sindranol Prolonged


Sorbifer durules


Stimuloton


Suprastin


Talliton


Tiregis-D


Tulosin

Velaxin

Zalain